Clinical Trial Update: Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating carfilzomib in combination with ibrutinib versus ibrutinib alone in Waldenström macroglobulinemia; the study is currently active but no…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• IMBRUVICA (IBRUTINIB)
• Kyprolis (carfilzomib)

Snippet

Sponsor: Christian Buske | Conditions: Waldenstrom Macroglobulinemia | Phase 2 | Status: ACTIVE_NOT_RECRUITING